Nutriband Advances Abuse-Deterrent Transdermal Drug Technology, Eyes 2025 Commercialization
Nutriband is positioning itself for potential market expansion by developing innovative abuse-deterrent transdermal pharmaceutical products with projected peak annual sales exceeding $330 million for its Fentanyl and Buprenorphine patches.
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in developing abuse-deterrent transdermal pharmaceutical technology, with CEO Gareth Sheridan outlining ambitious milestones for 2024 and 2025. The company is focusing on its AVERSA™ technology, which aims to prevent drug abuse, misuse, diversion, and accidental exposure.
The company's strategic partnership with Kindeva Drug Delivery is driving the development of AVERSA Fentanyl, with plans to conduct a pivotal Human Abuse Liability clinical trial and file a New Drug Application (NDA). Market projections suggest potential peak annual sales of $200 million for the Fentanyl patch and $130 million for the Buprenorphine patch.
Nutriband has expanded its global intellectual property protection, securing patents in 46 countries. The company also raised $8.4 million through a non-brokered placement, providing financial resources to support its continued development efforts.
In addition to its pharmaceutical technology, Nutriband expects revenue growth in 2025 through its Pocono Pharma subsidiary, bolstered by an existing partnership with KT Tape. These developments position the company as an emerging player in innovative drug delivery solutions with a strong focus on patient safety and abuse prevention.